The Diopsys lid sensor technology certainly revolutionized our ability to detect disease earlier and monitor treatment and disease progression with ERG testing.
Pine Brook, NJ (PRWEB) November 09, 2016
Diopsys, Inc. helps bring ERG testing out of the research lab and into clinical practice with a user- and patient-friendly sensor that produces reliable data. The latest advancement in electrode technology, the patented Diopsys® ERG Lid Sensor has transformed the eye care professional’s ability to perform reliable electroretinography (ERG) vision tests in their offices. The innovative sensor has a low-profile design which fits comfortably below the patient’s eye, and provides equivalent, and in some cases better results than previous electrodes.
Previously available sensors can make it difficult for eye care professionals to perform accurate ERG tests in their offices and usually involve a contact lens or wire being placed across the eye, which increases the potential for damage to the cornea. These invasive electrodes often require pre-application numbing eye drops and post-sterilization between patients. Not only is this inconvenient to the clinician and uncomfortable for the patient, it can lead to compliance issues and poor results due to the excessive blinking caused by the electrode touching the eye.
In some instances, the problems caused by invasive sensors have led to the use of generic skin electrodes, often designed for electromyography (EMG) or electrocardiography (EKG). The large size of these sensors often results in contact with facial muscles, which can produce inaccurate results. The Diopsys® ERG Lid Sensor was specifically designed for ERG testing to address the flaws of other electrodes.
“The fact that we now have an ERG electrode that our patients are happy with, our technicians are happy with, and that provides excellent ERG results allows us to get information about the retina that we couldn’t have before. The Diopsys lid sensor technology certainly revolutionized our ability to detect disease earlier and monitor treatment and disease progression with ERG testing,” said Mitchell Jackson, MD, Founder and CEO of Jacksoneye.
The patented Diopsys® ERG Lid Sensor underwent extensive development and design testing with leaders in the eye care field, including New York Eye and Ear Infirmary, Wills Eye Hospital, and Salus University. Research presented at the 2016 Association for Research in Vision and Ophthalmology (ARVO) meeting showed that the Diopsys® ERG Lid Sensor produces more repeatable amplitude results, and equivalent latency results compared to the older DTL and Ag/AgCl cup electrodes. Additional research using this advanced lid sensor technology showed the test-retest repeatability of Diopsys® ERG and Diopsys® ffERG vision tests ranged between good and excellent for all tested parameters.
For more information on Diopsys® ERG vision testing, please visit http://www.diopsys.com/erg.
Diopsys, Inc. (http://www.diopsys.com) is the leader in providing ophthalmologists and optometrists with objective, functional information to aid in the early detection of vision disorders and enhance patient management through ERG and VEP vision testing. Eye care providers can perform these objective, functional tests using the Diopsys® NOVA cart system, or the Diopsys® ARGOS™ tabletop system. The company understands the important role of early medical intervention for correctable vision problems, which can lead to an improved quality of life. Early detection means better patient outcomes.
1. Shengelia A. et al. Evaluation of pattern ERG responses using various electrodes. Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3943.
2. Resende A. et al. Repeatability of Steady-State Pattern Electroretinogram and Full-Field Electroretinogram using a novel office-based testing platform in normal subjects. Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3949.